AVID100 Featured in an Invited Oral Presentation at the 9th Annual World ADC Summit

  • Forbius will be providing an update on development of AVID100, an anti-EGFR ADC
  • Phase 1 established a high RP2D that is predicted to be therapeutically active; Phase 2a trials underway
  • AVID100 is the only broadly active anti-EGFR ADC in clinical development

(November 6, 2018) – Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, announced today an invited oral presentation of AVID100 at the 9th Annual World ADC Meeting. Robert Lutz, Chief Development Officer of Forbius, will give a presentation entitled "Preclinical & Clinical Development of AVID100: An EGFR-Targeting Antibody Drug Conjugate” on November 13, 2018 at 11 AM Pacific Time.

The AVID100 Phase 1 study was completed mid 2018, having enrolled 24 patients, and established a recommended Phase 2 dose (RP2D) of AVID100 of 240 mg/m2 (~6 mg/kg). This is one of the highest RP2Ds reported for maytansinoid payload ADCs (Deslandes, MAbs. 2014 Jul 1;6(4):859–870) and is expected to be in the therapeutically active range based on preclinical efficacy studies. The majority of treatment related adverse events at RP2D were well-tolerated and grade 1 and 2 in severity. Of note, skin-related side-effects, that have been observed previously for therapeutic anti-EGFR antibodies, remained low grade and well tolerated.

AVID100 is currently undergoing Phase 2a clinical trials in EGFR overexpressing tumors to further evaluate safety and efficacy.

About AVID100

AVID100 is a highly potent EGFR-targeting antibody-drug conjugate (ADC) that was engineered to achieve enhanced anti-tumor efficacy without a corresponding increase in toxicity against skin and other EGFR-expressing normal tissues. In preclinical studies, AVID100 demonstrated significant anti-cancer activity, including in EGFR overexpressing tumor models that are resistant to marketed EGFR inhibitors. AVID100 is the only broadly active anti-EGFR ADC in clinical development.

About Forbius (Formation Biologics)

Forbius is a clinical stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. Forbius’ medicines are designed to radically transform patients’ lives. We use our strength in biological understanding and diverse protein engineering technologies to design superior inhibitors of validated pathways. We have particularly deep expertise in targeting the transforming growth factor-beta (TGF-β) and epidermal growth factor receptor (EGFR) pathways. For both of these pathways, there is a significant body of evidence validating their role as drivers of multiple life-threatening conditions, including cancer and fibrosis. However, in the case of the EGFR pathway, the majority of patients do not benefit from currently marketed EGFR inhibitors; in the case of the TGF-β pathway, no agent targeting this pathway has yet been approved. By using multiple complementary platform technologies, Forbius’ team overcame barriers that prevented the development of effective therapeutics targeting these pathways.



Claudia Resch